Canagliflozin

Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class or subtype 2 sodium-glucose transport (SGLT-2) inhibitors used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.

Medical use

Canagliflozin is an anti-diabetic drug used to improve glycemic control in people with type 2 diabetes. In extensive clinical trials, canagliflozin produced a consistent dose-dependent decrease in HbA1c levels of 0.77% to 1.16% when administered either as monotherapy, in combination with metformin, in combination with metformin and a sulfonylurea, in combination with metformin and pioglitazone, or in combination with insulin, from initial HbA1c levels of 7.8% to 8.1%. When added to metformin, canagliflozin 100 mg daily was shown to be non-inferior to both sitagliptin 100 mg daily and glimepiride in reducing HbA1c levels at one year, whilst canagliflozin 300 mg successfully demonstrated statistical superiority over both sitagliptin and glimiperide in decreasing HbA1c levels. Secondary efficacy endpoints of higher reductions in weight and blood pressure (versus sitagliptin and glimiperide) were also observed in studies. Canagliflozin produces beneficial effects on HDL cholesterol whilst increasing LDL cholesterol to produce no change in total cholesterol.
Name: Canagliflozin
CAS No.: 842133-18-0
Molecular formula: C24H25FO5S
Molecular weight: 444.52.
Systematic name:(1S)-1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol.
ACD/LogP: 5.34±0.81
H bond acceptors: 5
H bond donors: 4
Freely Rotating Bonds: 9
Polar Surface Area: 118.39 Å2
Index of Refraction: 1.639
Molar Refractivity: 117.2±0.3 cm3
Molar Volume: 325.9±3.0 cm3
Polarizability: 46.5±0.5×10-24cm3
Surface Tension: 56.1±3.0 dyne/cm
Density: 1.4±0.1 g/cm3
Flash Point: 342.6±31.5 °C
Enthalpy of Vaporization: 99.7±3.0 kJ/mol
Boiling Point: 642.9±55.0 °C at 760 mmHg
Vapour Pressure: 0.0±2.0 mmHg at 25 °C
Canagliflozin is an experimental drug. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90 % of the glucose reabsorption in the kidney.
Specifications:

Tests
Specifications
Results
Appearance
White or off-white powder
White powder
Identification:
A. IR(KBr)
The sample spectrum corresponds to that of the working standard
Confirm
B. HPLC
The retention time of the major peak in the chromatogram of the sample

corresponds to that exhibited by the working standard
Confirm
Single impurity
Not more than 0.1%
0.08%
Total impurities
Not more than 1.0%
0.5%
E.e %
More than 98.5%
99%
Assay (by HPLC)
Not less than 98.0% and not more than 102.0% w/w
99.1%
Conclusion
Comply with In-house standard.
Storage
Store protected from light and moisture
Packaging & Shipping:

25kg/drum or according to customer’s requiement
Transit could be DHL,UPS,TNT,EMS,Fedex,and so on.
For mass orders, it will be delivered by air or sea.
Depending on your location, please allow 1-5 business days for your order to arrive.
For small order, please expect 3-7 days by UPS DHL EMS.
For mass order, please allow 5-8 days by Air, 15-30 days by Sea.

my contact infomation is:
Whatsapp: 008615032102186
Email: bettyapi1989@163.com

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body

Advertisements